Background: Subclinical hypothyroidism (SCH) is estimated to affect around 7.5-8.5% of females and 2.8-4.4% of males. One of the features of clinical hypothyroidism is dyslipidemia. There is a great debate about the presence of abnormal lipid profiles in patients with subclinical hypothyroidism (SCH) and weather it is clinically significant or not. Some evidences show reduction in the level of the serum lipid profile after replacement with thyroid hormones. The purpose of this study is to estimate the prevalence of dyslipidemia in patients with subclinical hypothyroidism in Duhok and Erbil cities, Iraq. Patients and Methods: This is a case-control study that was done on 200 individuals. One hundred patients confirmed with subclinical hypothyroidism were compared with a group of 100 apparently healthy individuals. These two groups were matched for age and sex. The study done in 2 centres; Azadi Teaching Hospital in Duhok and Rizgari Teaching Hospital in Erbil, Kurdistan Region, Iraq from from 1st December 2017 to 1st December 2018. Results: Dyslipidemia was commoner in patients with subclinical hypothyroidism compared to control group (p value 0.001) compared to the control group (p value 0.766). The total cholesterol and the triglyceride levels were steadily increased in relation to the level of the thyroid stimulating hormone (TSH). Conclusions: Subclinical hypothyroidism (SCH) is regarded as an atherogenic condition because it increases the cholesterol and the triglyceride levels. Management of subclinical hypothyroidism with thyroid hormones may have a positive impact on the cardiovascular health. It is reasonable to measure the levels of the serum lipids and cardiovascular risk in these patients and to manage them when it is clinically applicable. Duhok Med J 2019; 13 (1):65-65.
because it regulates the expression of different genes which control fat synthesis and catabolism 1, 2 .
Hypothyroidism is caused by decrease execration of thyroxin (T4) and T3. Biochemical reduction in T4 and T3 levels will lead to elevation in the serum thyroid stimulating hormone (TSH) level. In clinical hypothyroidism there is high cholesterol levels in the serum and a marked increase in low density lipoprotein (LDL) due to reduction in the catabolism of LDL by decreasing the number of LDL receptors in the hepatocytes. However, debate is present concerning the fat levels in Subclinical hypothyroidism (SCH) and its importance clinically 3, 4 .
Non-symptomatic individuals having elevated thyroid stimulating hormone level with the presence of normal freeT4 levels are called subclinical hypothyroidism. Subclinical hypothyroidism may be changed to overt hypothyroidism in many patients. Patients of SCH are usually nonsymptomatic or complain from minimum symptoms. For this reason, SCH is only a diagnosed by investigations 5 .
Clinical thyroid abnormalities may be suspected due to the presence of thyroid enlargement. This condition is common and may be seen in 6-17% of the people 6, 7 .
The presence of SCH is commoner in females more than in males and is estimated to be two times more common. All over the world around 7.5-8.5% of women and 2.8-4.4% of men have SCH.
The diagnosis depends on the biochemical analysis which is performed using the chemiluminiscence technique. The normal serum TSH level is 0.4 -4.5 m IU /L. SCH is one of the causes for coronary artery diseases, fat derangement, and congestive heart failure. In a new population-based study subclinical hypothyroidism appears to be an independent risk for the development of atherosclerosis of the aorta and ischemic heart diseases. Peri-menopausal women tend to have similar symptoms to hypothyroidism, so evaluation of thyroid hormones in such group of patients may diagnose subclinical hypothyroidism which may be missed easily 11, 12 .
Moreover, subclinical hypothyroidism may change to clinical hypothyroidism. The rate of progression is higher with the simultaneous presence of thyroid peroxidase antibodies or increase levels of TSH. Administration of a low dose of thyroid hormones cause a significant reduction in the level of the total cholesterol, non-HDL, LDL, and LDL to HDL values. Recent clinical evidence also shows that treatment with T4 therapy may improve lipid profile in the cases of subclinical hypothyroidism 13 .
MATERIALS AND METHODS
A total number of 200 individuals were included in this study, 100 patients diagnosed with subclinical hypothyroidism with 100 apparently healthy individuals as a control group (matched for age and gender), from 1st December 2017 to 1st December 2018. This study was done in the endocrine clinic at Azadi General Teaching Hospital in Duhok city and Rizgary Teaching Hospital in Erbil city. An informed consent was obtained from patients after explaining the study project. The detailed history was taken and the clinical examination was done for each patient. Each patient was given a special questionnaire to obtain information.
Inclusion and Exclusion Criteria
Inclusion criteria include patients having subclinical hypothyroidism, when TSH is greater than 5.0 m IU/L and the free-T3, the free-T4 are below the reference range which was done two times at six weeks in between each test result. Exclusion criteria include patients that have factors that alter thyroid function test such as pregnancy, oral contraceptive pills especially that contain only estrogen, steroids, amiodarone, and phenytoin, liver and kidney diseases, positive personal or family history of thyroid abnormalities, smokers, history of a recent surgical intervention and history of acute illness such as critical illness which causes abnormalities in thyroid hormone levels. Also Patients taking medications that lower the lipid levels have been excluded. In older patients, higher TSH (>6) used to diagnose subclinical hypothyroidism, patients more than 65 years of age have been excluded 14, 15 . 
Definition of Dyslipidemia

STATISTICAL METHODS
Statistical analyses were done using the Statistical Package for Social Science (SPSS); p values less than 0.05 were considered significant.
RESULTS
The majority of the patients in the study were between 40-50 years (53%) while 26% of the patients were between 50-60 years. Female patients constitute 53 % of the involved participants. The relation between the level of the TSH and the data taken from the patients showed a significant relation with the dyslipidemia (p value 0.001) and with the HDL (p value 0.002), while no factor had been found to be related to the TSH level in the control group. Other factors and their relation to the TSH are shown in Tables 1 and 2 . The relation between the dyslipidemia and the TSH levels is shown in Figure 1 , the level of the abnormal lipid profile is significantly high in patients in whom the TSH levels are higher than 5. The cholesterol and the triglycerides levels tend to be significantly higher in patients with TSH levels higher than 5, Figures 2 and 3. Data from our patients shows a very strong correlation between subclinical hypothyroidism and abnormal lipid profiles as it is found to be commoner in patients with SCH in when compared to the control group (p value 0.001 and 0.766) respectively, and this has the same clinical evidence comparing to the findings of numerous other studies worldwide, which also show similar correlation as in our study 22 .
Further interpretation of dyslipidemic patients; i.e., the cholesterol level and triglycerides level showed a significant increase in their levels when the level of the TSH also get higher. This in accordance to many other studies done in some parts of the globe. LDL level was greater in the patient group when compared to the control group. This relation is found to be statistically not so significant if its compared to the levels of the HDL which also showed a statistically significant value in the patients group (p value of 0.002) but there was no correlation with any of these in the control group. This statistical differences may reflection the pattern of dyslipidemia in the populations of this region and larger population based studies needed to prove or exclude this 23 .
Furthermore, evidence emerges that management with thyroid hormones decrease serum lipid levels in patients having SCH which may decrease the morbidities and the mortality from the cardiovascular events, for this reason it is very important to manage patients having SCH and dyslipidemia properly. Even a mild decrease in the cholesterol level of, triglycerides and the LDL may significantly decrease in the cardiac and the vascular morbidity in the future. Subclinical hypothyroidism is found to be an atherogenic status as it causes dyslipidemia and it enhances the cardiac and the vascular risk. Management of patients having subclinical hypothyroidism with thyroid hormones improves the quality of life and deaths from coronary vascular diseases. It's reasonable to measure the lipid profiles and cardiovascular risk factors in such patients and to manage them with thyroid hormones when it can be applied in clinical practice 24 . 
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